BACKGROUND: Juvenile nasopharyngeal angiofibroma (JNA) is a benign tumor that presents in adolescent males. Although surgical excision is the mainstay of treatment, recurrences complicate treatment. There is a need to develop less invasive approaches for management. JNA tumors are composed of fibroblasts and vascular endothelial cells. We identified fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor (VEGF) expression in JNA-derived fibroblasts. FGFR influences fibroblast proliferation and VEGF is necessary for angiogenesis. We hypothesized that targeting FGFR would mitigate JNA fibroblast proliferation, invasion, and migration, and that targeting the VEGF receptor would attenuate endothelial tubule formation. METHODS: After informed consent, fibroblasts from JNA explants of 3 patients were isolated. Fibroblasts were treated with FGFR inhibitor AZD4547, 0 to 25 μg/mL for 72 hours and proliferation was quantified using CyQuant assay. Migration and invasion of JNA were assessed using 24-hour transwell assays with subsequent fixation and quantification. Mitigation of FGFR and downstream signaling was evaluated by immunoblotting. Tubule formation was assessed in human umbilical vein endothelial cells (HUVECs) treated with vehicle control (dimethylsulfoxide [DMSO]) or semaxanib (SU5416) as well as in serum-free media (SFM) or JNA conditioned media (CM). Tubule length was compared between treatment groups. RESULTS: Compared to control, AZD4547 inhibited JNA fibroblast proliferation, migration, and invasion through inhibition of FGFR and downstream signaling, specifically phosphorylation of - p44/42 mitogen activated protein kinase (p44/42 MAPK). JNA fibroblast CM significantly increased HUVEC tubule formation (p = 0.0039). CONCLUSION: AZD4547 effectively mitigates FGFR signaling and decreases JNA fibroblast proliferation, migration, and invasion. SU5416 attenuated JNA fibroblast-induced tubule formation. AZD4547 may have therapeutic potential in the treatment of JNA.
BACKGROUND:Juvenile nasopharyngeal angiofibroma (JNA) is a benign tumor that presents in adolescent males. Although surgical excision is the mainstay of treatment, recurrences complicate treatment. There is a need to develop less invasive approaches for management. JNA tumors are composed of fibroblasts and vascular endothelial cells. We identified fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor (VEGF) expression in JNA-derived fibroblasts. FGFR influences fibroblast proliferation and VEGF is necessary for angiogenesis. We hypothesized that targeting FGFR would mitigate JNA fibroblast proliferation, invasion, and migration, and that targeting the VEGF receptor would attenuate endothelial tubule formation. METHODS: After informed consent, fibroblasts from JNA explants of 3 patients were isolated. Fibroblasts were treated with FGFR inhibitor AZD4547, 0 to 25 μg/mL for 72 hours and proliferation was quantified using CyQuant assay. Migration and invasion of JNA were assessed using 24-hour transwell assays with subsequent fixation and quantification. Mitigation of FGFR and downstream signaling was evaluated by immunoblotting. Tubule formation was assessed in human umbilical vein endothelial cells (HUVECs) treated with vehicle control (dimethylsulfoxide [DMSO]) or semaxanib (SU5416) as well as in serum-free media (SFM) or JNA conditioned media (CM). Tubule length was compared between treatment groups. RESULTS: Compared to control, AZD4547 inhibited JNA fibroblast proliferation, migration, and invasion through inhibition of FGFR and downstream signaling, specifically phosphorylation of - p44/42 mitogen activated protein kinase (p44/42 MAPK). JNA fibroblast CM significantly increased HUVEC tubule formation (p = 0.0039). CONCLUSION:AZD4547 effectively mitigates FGFR signaling and decreases JNA fibroblast proliferation, migration, and invasion. SU5416 attenuated JNA fibroblast-induced tubule formation. AZD4547 may have therapeutic potential in the treatment of JNA.
Authors: Paul R Gavine; Lorraine Mooney; Elaine Kilgour; Andrew P Thomas; Katherine Al-Kadhimi; Sarah Beck; Claire Rooney; Tanya Coleman; Dawn Baker; Martine J Mellor; A Nigel Brooks; Teresa Klinowska Journal: Cancer Res Date: 2012-02-27 Impact factor: 12.701
Authors: Brigitte C Widemann; Aerang Kim; Elizabeth Fox; Sylvain Baruchel; Peter C Adamson; Ashish M Ingle; Julia Glade Bender; Michael Burke; Brenda Weigel; Diana Stempak; Frank M Balis; Susan M Blaney Journal: Clin Cancer Res Date: 2012-09-07 Impact factor: 12.531
Authors: Sarah Elizabeth Wheeler; Huifang Shi; Fangchen Lin; Sumana Dasari; Joseph Bednash; Stephen Thorne; Simon Watkins; Radhika Joshi; Sufi Mary Thomas Journal: Head Neck Date: 2013-06-01 Impact factor: 3.147
Authors: Alejo Rodriguez-Vida; Matilde Saggese; Simon Hughes; Sarah Rudman; Simon Chowdhury; Neil R Smith; Peter Lawrence; Claire Rooney; Brian Dougherty; Donal Landers; Elaine Kilgour; Hendrik-Tobias Arkenau Journal: J Hematol Oncol Date: 2015-10-24 Impact factor: 17.388
Authors: Anne S Boewe; Silke Wemmert; Philipp Kulas; Bernhard Schick; Claudia Götz; Selina Wrublewsky; Mathias Montenarh; Michael D Menger; Matthias W Laschke; Emmanuel Ampofo Journal: Biomedicines Date: 2022-04-21
Authors: Joel W Jones; Shireen Usman; Jacob New; Andrew Holcomb; Sumedha Gunewardena; Ossama Tawfik; Larry Hoover; Daniel Bruegger; Sufi Mary Thomas Journal: Otolaryngol Head Neck Surg Date: 2018-04-10 Impact factor: 3.497